5 recruiting, 4 active not recruiting, 4 completed. 13 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 13 | Recruiting 5, Active not recruiting 4, Completed 4 |
| Phase 1 | 3 | Completed 2, Active not recruiting 1 |
Follow Grade 1 Follicular Lymphoma: new trials by email Literature Review of Grade 1 Follicular Lymphoma trials Research Report on Grade 1 Follicular Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Tafasitamab and Rituximab for the Treatment of Newly Diagnosed Follicular Lymphoma Rituximab, Tafasitamab, Biospecimen Collection - Classic Follicular Lymphoma, Grade 1 Follicular Lymphoma | Phase 2 | Recruiting | University of Washington | 30 | 2026-10-09 | 2026-10-15 |
| Pirtobrutinib and Mosunetuzumab for the Treatment of Relapsed/Refractory Grades 1-3A Follicular Lymphoma, PROMOTE-FL Trial Pirtobrutinib, Mosunetuzumab, Biospecimen Collection - Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma | Phase 2 | Recruiting | University of Washington | 22 | 2025-11-17 | 2026-06-04 |
| Low Dose Mosunetuzumab for the Treatment of Patients With Indolent B-Cell Lymphoma Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging - Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage II Marginal Zone Lymphoma | Phase 2 | Recruiting | University of Washington | 20 | 2024-08-29 | 2026-08-27 |
| Combination of Zanubrutinib, Rituximab and Venetoclax in Patients With Previously Untreated Follicular Lymphoma Zanubrutinib, Rituximab, Venetoclax - Ann Arbor Stage II Follicular Lymphoma, Grade 1 Follicular Lymphoma | Phase 2 | Recruiting | Chinese PLA General Hospital | 30 | 2024-07-10 | 2026-07-20 |
| Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma Mosunetuzumab, Obinutuzumab, Polatuzumab Vedotin - Non-Hodgkin Lymphoma, Grade 1 Follicular Lymphoma | Phase 2 | Completed | University of Washington | 42 | 2022-03-23 | 2026-05-13 |
| Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas Acalabrutinib, Obinutuzumab, Quality-of-Life Assessment - Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma | Phase 2 | Recruiting | Emory University | 49 | 2021-09-03 | 2026-02-09 |
| Obinutuzumab, Ibrutinib, and Venetoclax for the Treatment of Previously Untreated Stage II-IV Follicular Lymphoma Ibrutinib, Obinutuzumab, Venetoclax - Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage III Follicular Lymphoma | Phase 2 | Active not recruiting | University of California, Davis | 40 | 2021-02-24 | 2026-04-13 |
| Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma Acalabrutinib, Axicabtagene Ciloleucel - B-Cell Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Phase 1 / Phase 2 | Active not recruiting | University of Washington | 23 | 2020-12-02 | 2026-06-25 |
| Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas Ibrutinib, Obinutuzumab, Laboratory Biomarker Analysis - Non-Hodgkin's Lymphoma, Ann Arbor Stage II Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | Phase 2 | Active not recruiting | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 29 | 2018-02-20 | 2026-08-18 |
| Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma Bendamustine Hydrochloride, Biopsy Procedure, Biospecimen Collection - Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 73 | 2018-01-23 | 2026-07-08 |
| Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma Entospletinib, Laboratory Biomarker Analysis, Obinutuzumab - Anemia, B-Cell Prolymphocytic Leukemia | Phase 1 / Phase 2 | Completed | Alexey Danilov, MD | 24 | 2017-07-17 | 2023-08-08 |
| TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1-3A Follicular Lymphoma Ibrutinib, Radiation Therapy, TLR9 Agonist SD-101 - Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma | Phase 1 / Phase 2 | Completed | Robert Lowsky | 21 | 2016-11-07 | 2024-10-16 |
| Ibrutinib in Combination With Rituximab and Lenalidomide in Treating Patients With Previously Untreated, Stage II-IV Follicular Lymphoma or Marginal Zone Lymphoma Ibrutinib, Laboratory Biomarker Analysis, Lenalidomide - Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage II Marginal Zone Lymphoma | Phase 2 | Completed | M.D. Anderson Cancer Center | 48 | 2016-04-11 | 2024-09-24 |
Lymphoma, Follicular (13) · Lymphoma, B-Cell, Marginal Zone (4) · Lymphoma, Mantle-Cell (3) · Lymphoma, Non-Hodgkin (3) · Anemia (1) · Leukemia, Hairy Cell (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Leukemia, Prolymphocytic, B-Cell (1) · Lymphoma, B-Cell (1) · Lymphoma, Large B-Cell, Diffuse (1) · Lymphoproliferative Disorders (1)
Hemic and Lymphatic Diseases (13) · Immune System Diseases (13) · Immunoproliferative Disorders (13) · Lymphatic Diseases (13) · Lymphoma (13) · Neoplasms (13) · Neoplasms by Histologic Type (13) · Lymphoproliferative Disorders (12) · Lymphoma, Non-Hodgkin (10) · Lymphoma, B-Cell (4) · Chronic Disease (1) · Disease Attributes (1) · Hematologic Diseases (1) · Leukemia (1) · Leukemia, B-Cell (1)
obinutuzumab (6) · Magnetic Resonance Spectroscopy (5) · ibrutinib (4) · Biopsy (3) · Rituximab (3) · Specimen Handling (3) · CT-P10 (2) · Lenalidomide (2) · acalabrutinib (2) · venetoclax (2) · 6-(1H-indazol-6-yl)-N-(4-morpholinophenyl)imidazo(1,2-a)pyrazin-8-amine (1) · Bendamustine Hydrochloride (1) · Cyclophosphamide (1) · Disulfides (1) · Doxorubicin (1)
University of Washington (5) · Alexey Danilov, MD (1) · Chinese PLA General Hospital (1) · Emory University (1) · M.D. Anderson Cancer Center (1) · National Cancer Institute (NCI) (1) · Robert Lowsky (1) · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University (1) · University of California, Davis (1)
United States (12) · China (1)
Ajay Gopal (2) · Mengyang Di, MD, PhD (2) · Craig Okada, M.D. (1) · Jonathon B Cohen, MD, MS (1) · Joseph M Tuscano (1) · Loretta J Nastoupil (1) · Michael Khodadoust (1) · Paul M Barr (1) · Ronald Levy (1) · Ryan Lynch, MD (1) · Ubaldo Martinez-Outschoorn, MD (1)
PMID 34196037, PMID 34780125, PMID 37939259, PMID 37985359, PMID 42600120
P30CA093373 (1), P30CA138292 (1), R35CA197353 (1), U10CA180888 (1)